|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Real estate properties: | ||||||||||||||||||||
| Land | ||||||||||||||||||||
| Buildings and improvements | ||||||||||||||||||||
| Total real estate properties, gross | ||||||||||||||||||||
| Accumulated depreciation | ||||||||||||||||||||
| Total real estate properties, net | ||||||||||||||||||||
| Investment in unconsolidated joint venture | ||||||||||||||||||||
| Assets of properties held for sale | ||||||||||||||||||||
| Acquired real estate leases, net | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash and cash equivalents | ||||||||||||||||||||
| Rents receivable, including straight line rents of $124,507 and $114,199, respectively | ||||||||||||||||||||
| Deferred leasing costs, net | ||||||||||||||||||||
| Debt issuance costs, net | ||||||||||||||||||||
| Other assets, net | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND EQUITY | ||||||||||||||||||||
| Mortgage notes payable, net | ||||||||||||||||||||
| Liabilities of properties held for sale | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Accounts payable and other liabilities | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Assumed real estate lease obligations, net | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Equity: | ||||||||||||||||||||
| Common shares of beneficial interest, $.01 par value: 100,000,000 shares authorized; 67,001,208 and 66,653,129 shares issued and outstanding, respectively | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Cumulative net deficit | ||||||||||||||||||||
| Cumulative other comprehensive loss | ||||||||||||||||||||
| Cumulative common distributions | ||||||||||||||||||||
| Total equity attributable to common shareholders | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
Loading...
